Biomedical Development Articles & Analysis
58 news found
Medical probiotic leader Bened Biomedical Co., Ltd., which develops and markets neuroactive probiotic products, announced a completed Series A round of fundraising, receiving more than $10 million of capital from two prominent investors, Trans-Pacific Technology Fund (TPTF) and JAFCO Asia. ...
Lumen Bioscience — a clinical stage biopharmaceutical company developing biologic drugs for highly prevalent diseases — announced today preliminary results from a Biomedical Advanced Research and Development Authority (BARDA)-supported effort to develop an intranasal formulation of its drug candidate, LMN-301. ...
Lumen Bioscience—a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases—today announced the receipt of a $3.6 million award from the Department of Defense (DoD) for advanced biomedical product development in support of Naval operations. The award from the Medical Technology Consortium ...
NEW YORK, Oct. 12, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today provided an update on the status of multiple clinical trials now underway to assess the safety and efficacy of TPOXX to treat monkeypox. In recent weeks, randomized, placebo-controlled clinical trials were initiated in ...
Aktiv Pharma Group (Aktiv) today announced a procurement contract award from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. ...
The Funding Supports Development of an Intramuscular ENA-001 From Pre-Clinical Toxicology Through Filing for Approval in the United States Enalare Therapeutics Inc., a clinical stage biopharmaceutical company dedicated to developing novel compounds for the treatment of life-threatening critical care diseases and community medical threats, announced today that it ...
To learn more, visit www.aestherhealthcarespac.com. About Ocean Biomedical Ocean Biomedical, Inc. is a Providence, Rhode Island-based biopharma company with an innovative business model that accelerates the development and commercialization of scientifically compelling assets from research universities and medical centers. ...
To learn more, visit www.aestherhealthcarespac.com. About Ocean Biomedical Ocean Biomedical, Inc. is a Providence, Rhode Island based biopharma company with an innovative business model that accelerates the development and commercialization of scientifically compelling assets from research universities and medical centers. ...
The combined company will work to accelerate the development of Ocean Biomedical’s core assets in oncology, fibrosis, and infectious diseases, all based on new target discoveries enabling first-in-class drug and vaccine candidates – developed through past and ongoing grants totaling $123.9 million. ...
The combined company will work to accelerate the development of Ocean Biomedical’s core assets in oncology, fibrosis, and infectious diseases, all based on new target discoveries enabling first-in-class drug and vaccine candidates – developed through past and ongoing grants totaling $123.9 million. ...
Aesther Healthcare (NASDAQ:AEHA) announced this morning that it has inked a common stock purchase agreement with White Lion Capital that will provide up to $75 million to its combination target Ocean Biomedical. Following close, Ocean may direct White Lion to purchase shares in the company worth up to $2 million or 67% of the five-day average daily trading volume. ...
The combined company will work to accelerate the development of Ocean Biomedical’s core assets in oncology, fibrosis, and infectious diseases, all based on new target discoveries enabling first-in-class drug and vaccine candidates – developed through past and ongoing grants totaling $123.9 million. ...
This project builds on Celdara Medical’s Biomedical Industry Fellowship that promotes entrepreneurial skills development in biotech for senior graduate students and postdoctoral fellows. The A-CHEF program will train rising scientists in biomedical entrepreneurship and drug development. Through formal mentorship from the ...
"We are honored to receive this important grant award," stated Joseph Pergolizzi M.D., Chief Research and Development Officer of Enalare. "This funding supports further development of ENA001, which we believe has the potential to improve the standard of care in treating drug-induced respiratory depression with its unique mechanism of action as an agnostic ...
Proceeds will support product development and expansion of in-house cGMP manufacturing capabilities Company anticipates initiating Phase 2 trial of CRISPR-Cas3-enhanced bacteriophage precision medicine for UTIs mid-2022 Locus Biosciences, Inc. ...
Zerhouni brings extensive experience in academia, government and industry as a leading authority on emerging trends and issues in medical care and biomedical research and development. A physician scientist with an academic background in imaging and biomedical engineering, Dr. ...
Berkshire Biomedical Corporation (“Berkshire” or “the Company”), focused on developing its proprietary, hand-held, automated personalized drug dispensing technology to enhance patient wellness, today announced its support and recognition of the DEA’s National Prescription Drug Take Back Day on April 30, 2022. ...
The company is progressing investigational next generation antibodies that are active against the currently circulating variants of concern, and has initiated a first-in-human clinical trial of one of these next generation antibodies. The development and manufacturing of REGEN-COV have been funded in part with federal funds from the Biomedical Advanced Research ...
Affinity Biosensors Ultra-Rapid Phenotypical AST by Microbe Mass Measurement has been selected as a Step 1 semifinalist in the Antimicrobial Resistance Rapid, Point-of-Need Diagnostic Test Challenge by the National Institutes of Health (NIH) and the Biomedical Advanced Research and Development Authority (BARDA) of the Office of the Assistant Secretary for ...
Visby Medical™, a leading medical diagnostic company, today announced that it has received an additional $25.5M in federal funding to develop and validate an at-home combination Flu-Covid test from the Biomedical Advanced Research and Development Authority (BARDA).The developmental-stage Flu-COVID PCR Test is a single-use, handheld, ...